5077472025-04-012025-06-305077472025-06-305077472025-04-012025-06-30in-capmkt:OtherExpenses1Member5077472025-04-012025-06-30in-capmkt:ReportableSegments1Member5077472025-04-012025-06-30in-capmkt:ReportableSegments2Member5077472025-04-012025-06-30in-capmkt:ReportableSegments3Member5077472025-04-012025-06-30in-capmkt:ReportableSegments4Member5077472025-04-012025-06-30in-capmkt:ReportableSegments5Member5077472025-04-012025-06-30in-capmkt:ReportableSegments6Member5077472025-04-012025-06-30in-capmkt:ReportableSegments1Member5077472025-04-012025-06-30in-capmkt:ReportableSegments2Member5077472025-04-012025-06-30in-capmkt:ReportableSegments3Member5077472025-04-012025-06-30in-capmkt:ReportableSegments4Member5077472025-04-012025-06-30in-capmkt:ReportableSegments5Member5077472025-04-012025-06-30in-capmkt:ReportableSegments6Member5077472025-04-012025-06-30in-capmkt:ReportableSegments1Member5077472025-06-30in-capmkt:ReportableSegments1Member5077472025-04-012025-06-30in-capmkt:ReportableSegments2Member5077472025-06-30in-capmkt:ReportableSegments2Member5077472025-04-012025-06-30in-capmkt:ReportableSegments3Member5077472025-06-30in-capmkt:ReportableSegments3Member5077472025-04-012025-06-30in-capmkt:ReportableSegments4Member5077472025-06-30in-capmkt:ReportableSegments4Member5077472025-04-012025-06-30in-capmkt:ReportableSegments5Member5077472025-06-30in-capmkt:ReportableSegments5Member5077472025-04-012025-06-30in-capmkt:ReportableSegments6Member5077472025-06-30in-capmkt:ReportableSegments6Member5077472025-04-012025-06-30in-capmkt:ReportableSegments1Member5077472025-06-30in-capmkt:ReportableSegments1Member5077472025-04-012025-06-30in-capmkt:ReportableSegments2Member5077472025-06-30in-capmkt:ReportableSegments2Member5077472025-04-012025-06-30in-capmkt:ReportableSegments3Member5077472025-06-30in-capmkt:ReportableSegments3Member5077472025-04-012025-06-30in-capmkt:ReportableSegments4Member5077472025-06-30in-capmkt:ReportableSegments4Member5077472025-04-012025-06-30in-capmkt:ReportableSegments5Member5077472025-06-30in-capmkt:ReportableSegments5Member5077472025-04-012025-06-30in-capmkt:ReportableSegments6Member5077472025-06-30in-capmkt:ReportableSegments6Member5077472025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares507747TTKHLTCARENOTLISTEDINE910C01018TTK HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312025-08-04INRLakhsQuarterlyFirst quarterMulti segment2025-08-0412:00:002025-08-0412:50:00Not applicablefalsefalseThere is no Default on loans and Debt Securities, hence Not Applicable2025-04-012025-06-30UnauditedStandalone226429800017935600024436540004956720004702740005224000041330800076960002188100080604800022671190001765350000176535000465000004100046541000012999400000001299940005719000135713000141303000109.29.2009.29.21 The above financial results for the First Quarter ended June 30 2025 in respect of TTK Healthcare Limited the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 04 2025 at the Registered Office of the Company also with the provision of Video Conferencing facility <BR> <BR> 2 The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 <BR> <BR> 3 a During the first quarter of the previous year the Company had sold Leasehold land with building at Mahindra World City Chennai for a consideration of Rs 2300 lakhs and the profit on sale amounting to Rs 197705 lakhs Net has been considered in the above results <BR> <BR> b During the fourth quarter of the previous year the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs 58639 lakhs that were meant for export under USAID Program owing to a 90 day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom made and not marketable to alternate buyers <BR> <BR> 4 The figures for the Quarter ended March 31 2025 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures up to the end of the Third Quarter of the relevant financial year which were subjected to Limited Review <BR> <BR> 5 The previous periods years figures have been regrouped and reclassified wherever necessary to conform to the current periods years presentation <BR> <BR> 6 The full financial results for the First Quarter ended June 30 2025 are available on the website of BSE Limited www bseindia com National Stock Exchange of India Limited www nseindia com and also on the website of the Company www ttkhealthcare com <BR> Other Expenses806048000Animal Welfare318839000Consumer Products756304000Medical Devices288680000Protective Devices527124000Foods372433000Others918000226429800002264298000Animal Welfare23413000Consumer Products12571000Medical Devices80681000Protective Devices-54434000Foods29411000Others782000924240007696000-91807000176535000Animal Welfare397040000Consumer Products503332000Medical Devices827100000Protective Devices1385190000Foods673807000Others296020003816071000929258600013108657000Animal Welfare276903000Consumer Products646254000Medical Devices181950000Protective Devices427446000Foods158740000Others1364300017049360006175260002322462000Notes <BR> 1 Segments have been identified in line with the Indian Accounting Standard on Segment Reporting Ind AS 108 based on review of performance by the Top Management <BR> 2 Details of products included in each of the Segments are as below <BR> Animal Welfare comprise products for Veterinary use <BR> Consumer Products comprise marketing and distribution of Woodwards Gripewater EVA Range of Cosmetics Good Home Range of Scrubbers Air Fresheners etc <BR> Medical Devices include Artificial Heart Valves Orthopaedic Implants etc <BR> Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products <BR> Foods comprise manufacturing and marketing of Food Products <BR> Others include Printing and Publishing of Maps and Atlases <BR> 3 The segment wise revenue results assets and liabilities figures relate to respective amounts directly identifiable to each of the segments The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment <BR> 4 The previous periods years figures have been regrouped and reclassified wherever necessary to conform to the current periods years presentationItems that will not be reclassified subsequently to profit or loss5945000594500022600005719000